Modality
ERT
MOA
HPK1i
Target
PARP
Pathway
JAK/STAT
SCLC
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
~Dec 2020
→ ~Mar 2022
Phase 3
~Jun 2022
→ ~Sep 2023
NDA/BLA
Dec 2023
→ Jan 2028
NDA/BLACurrent
NCT07585960
93 pts·SCLC
2023-12→2028-01·Terminated
93 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-211.8y awayPh3 Readout· SCLC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-01-21 · 1.8y away
SCLC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07585960 | NDA/BLA | SCLC | Terminated | 93 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |